Rallybio Corporation
RLYB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.11 | -0.07 | -0.29 |
| FCF Yield | -117.89% | -62.35% | -27.43% | -14.96% |
| EV / EBITDA | -0.46 | -1.00 | -2.33 | -2.89 |
| Quality | ||||
| ROIC | -93.53% | -71.89% | -39.92% | -25.99% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 0.81 | 0.86 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 18.24% | -5.13% | -25.01% | -106.83% |
| Safety | ||||
| Net Debt / EBITDA | 0.23 | 0.33 | 0.86 | 3.86 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -4,564.80 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -774.58 | -2,374.93 | -2,434.79 | -2,019.22 |